Data / Form D filings / Antiva Biosciences, Inc.
Antiva Biosciences, Inc.: Form D filings
Antiva Biosciences, Inc., a biotechnology company in Redwood City, CA, filed 11 Form D notices with the SEC between 2013 and 2024. The latest, on October 11, 2024, reports $38.5 million sold of a $53 million offering to 21 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 555 Twin Dolphin Drive, Suite 620, Redwood City, CA, 94065
- Phone
- (650) 906-9229
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1563355
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 11, 2024 | Amendment | $52,999,990 | $38,535,985 | $14,464,005 | 21 | Apr 24, 2023 | sec.gov |
| May 5, 2023 | New notice | $52,999,990 | $26,565,771 | $26,434,219 | 21 | Apr 24, 2023 | sec.gov |
| Nov 3, 2021 | New notice | $31,001,635 | $15,639,364 | $15,362,271 | 20 | Oct 25, 2021 | sec.gov |
| Jul 19, 2018 | New notice | $15,000,000 | $15,000,000 | 8 | Jul 6, 2018 | sec.gov | |
| Aug 28, 2017 | Amendment | $25,941,512 | $14,740,756 | $11,200,756 | 15 | Feb 15, 2017 | sec.gov |
| Apr 5, 2017 | New notice | $22,341,512 | $11,140,756 | $11,200,756 | 13 | Feb 15, 2017 | sec.gov |
| Jun 11, 2015 | New notice | $15,969,973 | $8,907,483 | $7,062,490 | 26 | May 27, 2015 | sec.gov |
| Dec 23, 2014 | New notice | $2,545,018 | $1,745,019 | $799,999 | 19 | Dec 8, 2014 | sec.gov |
| Jul 10, 2014 | New notice | $1,300,000 | $1,100,000 | $200,000 | 14 | Jun 24, 2014 | sec.gov |
| Sep 5, 2013 | Amendment | $1,126,006 | $1,126,006 | 18 | Feb 26, 2013 | sec.gov | |
| Mar 6, 2013 | New notice | $1,001,006 | $501,006 | $500,000 | 6 | Feb 26, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Clifford Samuel | Director | |
| Beni Rovinski | Director | |
| Florencia Segal | Director | |
| Gail Maderis | Director | |
| Kristine Ball | Executive Officer, Director | |
| Elaine Chien | Executive Officer | |
| Brian Goodman | Director | |
| Wende Hutton | Director | |
| Sarah Walter | Executive Officer | |
| Raju Gadiraju | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Oct 7, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Antiva Biosciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.